Remit - To appraise the clinical and cost effectiveness of crizanlizumab within its marketing authorisation for preventing sickle cell crises in sickle cell disease
|
Status
|
In progress
|
| Process |
STA 2018
|
| ID number |
1406
|
Provisional Schedule
| Expected publication |
27 January 2021 |
Project Team
Email enquiries
| Evidence Review Group / Assessment Group |
Kleijnen Systematic Reviews Ltd |
Consultees
| Companies sponsors |
Novartis (crizanlizumab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Sickle Cell and Young Stroke Survivors (SCYSS) |
| |
Sickle Cell Society |
| Professional groups |
Royal College of Paediatrics and Child Health |
| |
Royal College of Physicians |
Commentators
| Comparator companies |
Bristol-Myers Squibb (hydroxycarbamide) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
|
Date
|
Update
|
|
26 November 2020 - 17 December 2020
|
Appraisal consultation |
|
04 November 2020
|
Committee meeting: 1 |
|
06 April 2020
|
In progress. Topic is in progress |
|
06 April 2020
|
Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear. |
|
03 December 2019
|
Following a regulatory update from the company, Novartis Pharmaceuticals, the timings for this appraisal have been amended, The first committee meeting has been rescheduled to 4 November 2020. |
|
25 October 2019
|
Invitation to participate |
|
22 March 2019 - 19 April 2019
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance